Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Expert Review of Respiratory Medicine
|
May 19, 2010
Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment
Clorinda Schettino, Maria Anna Bareschino, Vincenzo Ricci, et al.
Differentiation; Research in Biological Diversity
|
July 5, 2007
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
Floriana Morgillo, Maria Anna Bareschino, Roberto Bianco, et al.
The Oncologist
|
August 4, 2007
Erlotinib in non-small cell lung cancer treatment: current status and future development
Cesare Gridelli, Maria Anna Bareschino, Clorinda Schettino, et al.
Expert Opinion on Pharmacotherapy
|
August 13, 2010
Advances in chemotherapy in advanced non-small-cell lung cancer
Paolo Maione, Antonio Rossi, Paola Claudia Sacco, et al.
Expert Opinion on Investigational Drugs
|
April 7, 2010
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer
Cesare Gridelli, Antonio Rossi, Maria Anna Bareschino, et al.
Journal of Thoracic Disease
|
January 21, 2012
Treatment of advanced non small cell lung cancer
Maria Anna Bareschino, Clorinda Schettino, Antonio Rossi, et al.
Expert Opinion on Drug Safety
|
January 26, 2011
Pemetrexed in advanced non-small cell lung cancer
Cesare Gridelli, Paolo Maione, Antonio Rossi, et al.
Clinical Lung Cancer
|
January 12, 2008
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics
Cesare Gridelli, Antonio Rossi, Floriana Morgillo, et al.
Current Medicinal Chemistry
|
February 17, 2010
The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making
Antonio Rossi, Paolo Maione, Maria Anna Bareschino, et al.
Journal of Personalized Medicine
|
December 23, 2022
Pancreatic Cancer: Beyond Brca Mutations
Vincenzo Ricci, Teresa Fabozzi, Maria Anna Bareschino, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Expert Review of Respiratory Medicine
|
May 19, 2010
Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment
Clorinda Schettino, Maria Anna Bareschino, Vincenzo Ricci, et al.
Differentiation; Research in Biological Diversity
|
July 5, 2007
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy
Floriana Morgillo, Maria Anna Bareschino, Roberto Bianco, et al.
The Oncologist
|
August 4, 2007
Erlotinib in non-small cell lung cancer treatment: current status and future development
Cesare Gridelli, Maria Anna Bareschino, Clorinda Schettino, et al.
Expert Opinion on Pharmacotherapy
|
August 13, 2010
Advances in chemotherapy in advanced non-small-cell lung cancer
Paolo Maione, Antonio Rossi, Paola Claudia Sacco, et al.
Expert Opinion on Investigational Drugs
|
April 7, 2010
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer
Cesare Gridelli, Antonio Rossi, Maria Anna Bareschino, et al.
Journal of Thoracic Disease
|
January 21, 2012
Treatment of advanced non small cell lung cancer
Maria Anna Bareschino, Clorinda Schettino, Antonio Rossi, et al.
Expert Opinion on Drug Safety
|
January 26, 2011
Pemetrexed in advanced non-small cell lung cancer
Cesare Gridelli, Paolo Maione, Antonio Rossi, et al.
Clinical Lung Cancer
|
January 12, 2008
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics
Cesare Gridelli, Antonio Rossi, Floriana Morgillo, et al.
Current Medicinal Chemistry
|
February 17, 2010
The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making
Antonio Rossi, Paolo Maione, Maria Anna Bareschino, et al.
Journal of Personalized Medicine
|
December 23, 2022
Pancreatic Cancer: Beyond Brca Mutations
Vincenzo Ricci, Teresa Fabozzi, Maria Anna Bareschino, et al.
Page
of 3